Key result
Natriuretic peptides provide diagnostic and prognostic value across cardiovascular, respiratory, and COVID-19 dysfunctions.
Why the study?
This narrative review was conducted to assess the physiology and predictive values of ANP and BNP as biomarkers, comparing their relevance in settings and diseases associated with respiratory dysfunctions.
Answers are grounded in this paper and cite their sources.
This narrative review summarizes the physiological roles and predictive values of natriuretic peptides, particularly ANP and BNP, in differentiating cardiac from pulmonary causes of dyspnea and their prognostic utility in heart failure and COVID-19.
Natriuretic peptides (NPs) encompass a family of structurally related hormone/paracrine factors acting through the natriuretic peptide system regulating cell proliferation, vessel tone, inflammatory processes, neurohumoral pathways, fluids, and electrolyte balance. The three most studied peptides are atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-Type natriuretic peptide (CNP). ANP and BNP are the most relevant NPs as biomarkers for the diagnosis and prognosis of heart failure and underlying cardiovascular diseases, such as cardiac valvular dysfunction, hypertension, coronary artery disease, myocardial infarction, persistent arrhythmias, and cardiomyopathies. Cardiac dysfunctions related to cardiomyocytes stretching in the atria and ventricles are primary elicitors of ANP and BNP release, respectively. ANP and BNP would serve as biomarkers for differentiating cardiac versus noncardiac causes of dyspnea and as a tool for measuring the prognosis of patients with heart failure; nevertheless, BNP has been shown with the highest predictive value, particularly related to pulmonary disorders. Plasma BNP has been reported to help differentiate cardiac from pulmonary etiologies of dyspnea in adults and neonates. Studies have shown that COVID-19 infection also increases serum levels of N-terminal pro b-type natriuretic peptide (NT-proBNP) and BNP. This narrative review assesses aspects of ANP and BNP on their physiology, and predictive values as biomarkers. We present an overview of the NPs' synthesis, structure, storage, and release, as well as receptors and physiological roles. Following, considerations focus on ANP versus BNP, comparing their relevance in settings and diseases associated with respiratory dysfunctions. Finally, we compiled data from guidelines for using BNP as a biomarker in dyspneic patients with cardiac dysfunction, including its considerations in COVID-19.
No takes yet. Share an insight, caveat, or question.
Samad et al. (2023) conducted a review in Cardiovascular and respiratory dysfunctions (e.g., heart failure, COPD, COVID-19). Natriuretic peptides (BNP, ANP, NT-proBNP) as biomarkers was evaluated. Natriuretic peptides, particularly BNP and NT-proBNP, are valuable biomarkers for diagnosing and assessing the prognosis of cardiovascular and respiratory dysfunctions, including COVID-19.
Synapse has enriched 10 related papers. Consider them for comparative context: